J Korean Orthop Assoc.  2008 Apr;43(2):227-233. 10.4055/jkoa.2008.43.2.227.

Intraarticular Corticosteroids Modulate the Osteoprotegerin/Receptor Activator of Nuclear Factor-kappaB Ligand System in the Synovial Fluid in Patients with Rheumatoid Arthritis

• Lee JS
• Suh JT

• KMID: 2106444
• DOI: http://doi.org/10.4055/jkoa.2008.43.2.227

Abstract

PURPOSE: Despite the fact that intraarticular corticosteroids are a longstanding adjuvant treatment for inflammatory arthritis, their mechanisms of action are not completely understood. This study evaluated the osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) levels in the serum and synovial fluid before and 2 weeks after injecting intraarticular corticosteroid.
MATERIALS AND METHODS
Sixty seven patients were identified with joint effusions of the knee and suffering from rheumatoid arthritis. All the patients received an intraarticular injection of 40 mg of triamcinolone acetonide. The sera and synovial fluid were obtained before and 2 weeks after the injections. the erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, serum OPG and RANKL levels and synovial OPG and RANKL levels were measured before and 2 weeks after the injections.
RESULTS
The intraarticular corticosteroids induced a significant decrease in the levels of synovial RANKL. The decrease in the level of synovial RANKL caused a significant increase in the synovial OPG/RANKL ratio. There were no changes in the hematological factors, serum OPG, serum RANKL or synovial OPG observed after the corticosteroid injection.
CONCLUSION
Treatment with intraarticular corticosteroids modulates the OPG/RANKL system in the synovial fluid toward a bone-protective effect in patients with rheumatoid arthritis. This mechanism might explain part of the mode of action of intraarticular corticosteroids.

Keyword

Rheumatod arthritis; Intraarticular corticosteroid; Osteoprotegerin; Receptor activator of nuclear factor-kappaB ligand

MeSH Terms

Adrenal Cortex Hormones
Arthritis
Arthritis, Rheumatoid
Blood Sedimentation
C-Reactive Protein
Humans
Injections, Intra-Articular
Joints
Knee
Osteoprotegerin
RANK Ligand
Rheumatoid Factor
Stress, Psychological
Synovial Fluid
Triamcinolone Acetonide
Adrenal Cortex Hormones
C-Reactive Protein
Osteoprotegerin
RANK Ligand
Rheumatoid Factor
Triamcinolone Acetonide

Reference

1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988. 31:315–324.

2. Conaghan PG, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum. 2003. 48:64–71.

3. Goldring SR, Gravallese EM. Pathogenesis of bone lesions in rheumatoid arthritis. Curr Rheumatol Rep. 2002. 4:226–231.

4. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum. 2000. 43:2143–2151.

5. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000. 43:250–258.

6. Haynes DR, Barg E, Crotti TN, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford). 2003. 42:123–134.

7. Hirayama T, Sabokbar A, Athanasou NA. Effect of corticosteroids on human osteoclast formation and activity. J Endocrinol. 2002. 175:155–163.

8. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-KappaB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001. 79:243–253.

9. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 1999. 25:255–259.

10. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004. 292:490–495.

11. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology. 1998. 139:4743–4746.

12. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today. 2000. 21:495–502.

13. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998. 93:165–176.

14. Makrygiannakis D, af Klint E, Catrina SB, et al. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. Arthritis Rheum. 2006. 54:1463–1472.

15. Möttönen TT, Hannonen PJ, Boers M. Combination DMARD therapy including corticosteroids in early rheumatoid arthritis. Clin Exp Rheumatol. 1999. 17:6 Suppl 18. S59–S65.

16. Reid IR. Glucocorticoid osteoporosis--mechanisms and management. Eur J Endocrinol. 1997. 137:209–217.

17. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003. 111:821–831.

18. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone. 2002. 30:340–346.

19. Seshasayee D, Wang H, Lee WP, et al. A novel in vivo role for osteoprotegerin lignad in activation of monocyte effector function and inflammatory response. J Biol Chem. 2004. 279:30202–30209.

20. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000. 43:259–269.

21. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003. 102:1064–1069.

22. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004. 15:457–475.

23. Walsh MC, Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003. 14:251–263.

24. Walsh NC, Gravallese EM. Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol. 2004. 16:419–427.

25. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997. 272:25190–25194.